<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01996267</url>
  </required_header>
  <id_info>
    <org_study_id>M13TRT</org_study_id>
    <nct_id>NCT01996267</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2</brief_title>
  <acronym>TRAIN-2</acronym>
  <official_title>Optimizing Neoadjuvant Systemic Treatment for HER2 Positive Breast Cancer - the TRAIN-2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Borstkanker Onderzoek Groep</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares two schedules of upfront chemotherapy in HER positive breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upfront trastuzumab treatment is beneficial to patients with HER2 positive breast cancer. The
      potential synergistic cardiotoxicity of trastuzumab and anthracyclines has led to the
      development of non-anthracycline containing regimens, which have shown high pathologic
      complete response rates. Anthracyclines remain very active in HER2 positive breast cancer,
      however, and increasing evidence now supports safe combination of trastuzumab and epirubicin.
      Therefore, the addition of epirubicin to a non-anthracycline containing regimen may further
      improve outcome for patients with HER2 positive breast cancer.

      Several reports confirmed benefit of dual HER2 blockade by adding pertuzumab to a trastuzumab
      containing neoadjuvant regimen. The results of the combined treatment in the Neosphere study,
      however, are similar to what we found in a phase II trial using a weekly paclitaxel,
      trastuzumab, carboplatin combination with pCR rates of approximately 44%. Adding pertuzumab
      to this regimen is likely to also increase the high pCR rate and to add substantial benefit
      to patients.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with pathological complete response</measure>
    <time_frame>at week 30</time_frame>
    <description>To compare the efficacy of six cycles neoadjuvant PTC plus pertuzumab preceded by either three cycles of FEC-T plus pertuzumab or three cycles of PTC plus pertuzumab in HER2 positive breast cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with grade &gt;2 adverse events as a measure of safety and tolerability</measure>
    <time_frame>up to week 35</time_frame>
    <description>to describe the safety of the various regimens toxicity is compared between the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>identify prognostic and predictive biomarkers for pCR</measure>
    <time_frame>within one year after end of treatment</time_frame>
    <description>To identify prognostic and predictive biomarkers for pCR after neoadjuvant treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">437</enrollment>
  <condition>Breast Cancer</condition>
  <condition>HER2 Positive</condition>
  <arm_group>
    <arm_group_label>FEC-T +Pertuzumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluorouracil; 500 mg/m2; day 1 Epirubicine; 90 mg/m2; day 1 Cyclophosphamide; 500 mg/m2; day 1 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg) Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle is repeated every 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTC+Pertuzumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel; 80 mg/m2; day 1,8 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg); day 1 Carboplatin; AUC=6; day 1 Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle repeated every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTC+Pertuzumab</intervention_name>
    <description>Cycle repeated every 21 days</description>
    <arm_group_label>PTC+Pertuzumab</arm_group_label>
    <other_name>Paclitaxel; 80 mg/m2; day 1,8</other_name>
    <other_name>Trastuzumab; 6 mg/kg (loading dose 8 mg/kg); day 1</other_name>
    <other_name>Carboplatin; AUC=6; day 1</other_name>
    <other_name>Pertuzumab; 420 mg (loading dose 840 mg); day 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FEC-T+Pertuzumab</intervention_name>
    <description>Cycle is repeated every 21 days</description>
    <arm_group_label>FEC-T +Pertuzumab</arm_group_label>
    <other_name>Fluorouracil; 500 mg/m2; day 1</other_name>
    <other_name>Epirubicine; 90 mg/m2; day 1</other_name>
    <other_name>Cyclophosphamide 500 mg/m2; day 1</other_name>
    <other_name>Trastuzumab; 6 mg/kg (loading dose 8 mg/kg)</other_name>
    <other_name>Pertuzumab; 420 mg (loading dose 840 mg); day 1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed infiltrating breast cancer

          -  Stage II or stage III disease. Nodal status must be examined by ultrasound, fine
             needle aspiration, sentinel node biopsy, or FDG-PET scan.

          -  Overexpression and/or amplification of HER2 in an invasive component of the core
             biopsy, according to one of the following definitions:

             •&gt;30% of invasive tumor cells showing strong complete circumferential membrane
             staining (score 3+)

             •HER2 gene amplification defined as &gt;6 HER2 gene copies per nucleus by in situ
             hybridization.

          -  Age ≥18

          -  Eastern Cooperative Oncology Group performance status ≤1

          -  Adequate bone marrow function (ANC &gt;1.5 x 109/l, platelets &gt;100 x 109/l)

          -  Adequate hepatic function (ALAT, ASAT and bilirubin &lt;2.5 times upper limit of normal)

          -  Adequate renal function (creatinine clearance &gt;50 ml/min)

          -  LVEF ≥50% measured by echocardiography or MUGA

          -  Absence of any psychological, familial, sociological, or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule

          -  Absence of any medical condition that would place the patient at unusual risk.

          -  Signed written informed consent

        Exclusion Criteria:

          -  previous radiation therapy or chemotherapy

          -  other malignancy except carcinoma in situ, unless the other malignancy was treated ≥5
             years ago with curative intent without the use of chemotherapy or radiation therapy.

          -  current pregnancy or breastfeeding. Women of childbearing potential must use adequate
             contraceptive protection

          -  evidence of distant metastases. Evaluation of the presence of distant metastases may
             include chest X-ray, liver ultrasound, isotope bone-scan, CT-scan of chest and abdomen
             and/or FDG-PET scan, according to local procedures.

          -  evidence of bilateral infiltrating breast cancer. Evaluation of the presence of
             bilateral infiltrating breast cancer may include mammography, breast ultrasound and/or
             MRI breast.

          -  concurrent anti-cancer treatment or another investigational drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabe S Sonke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antoni van Leeuwenhoek, Amsterdam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MCA</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZGT</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZVU</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <zip>1090 HM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rode Kruis Ziekenhuis</name>
      <address>
        <city>Beverwijk</city>
        <zip>1940 EB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia ziekenhuis</name>
      <address>
        <city>Breda</city>
        <zip>4819 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Groep</name>
      <address>
        <city>Delft</city>
        <zip>2625 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Hospital</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haga</name>
      <address>
        <city>Den Haag</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronovo Ziekenhuis</name>
      <address>
        <city>den Haag</city>
        <zip>2597 AX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deventer ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <zip>6716 RP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5602 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Eindhoven</city>
        <zip>5631 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Anna Geldrop</name>
      <address>
        <city>Geldrop</city>
        <zip>5664 EH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orbis Medisch Centrum</name>
      <address>
        <city>Geleen</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groene Hart</name>
      <address>
        <city>Gouda</city>
        <zip>2803 HH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennemer Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <zip>2035 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium Medisch Centrum Parkstad</name>
      <address>
        <city>Heerlen</city>
        <zip>6401 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westfries Gasthuis</name>
      <address>
        <city>Hoorn</city>
        <zip>1624 NP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCL</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diaconessenhuis Meppel</name>
      <address>
        <city>Meppel</city>
        <zip>7943 KA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canisius-Wilhelmina Hospital</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waterlandziekenhuis</name>
      <address>
        <city>Purmerend</city>
        <zip>1441 RN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vlietland Ziekenhuis</name>
      <address>
        <city>Schiedam</city>
        <zip>3100 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diaconessenhuis Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3582 KE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VieCuri Medisch Centrum voor Noord-Limburg</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zaans Medisch Centrum</name>
      <address>
        <city>Zaandam</city>
        <zip>1502 DV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2013</study_first_submitted>
  <study_first_submitted_qc>November 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neoadjuvant</keyword>
  <keyword>breast cancer</keyword>
  <keyword>HER2 positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

